Search results
Showing 61 to 75 of 87 results for hepatitis c
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
None. Source guidance details Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.
Learning disability: care and support of people growing older (QS187)
This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.
View quality statements for QS187Show all sections
details Comes from guidance Sofosbuvir for treating chronic hepatitis C Number TA330 Date issued February 2015 Other
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.
of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with neurogenic lower...
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)
Boceprevir is no longer available in the UK so this guidance has been withdrawn.
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities